NSABP B-56-I

NSABP B-56-I

A Randomized, Placebo-Controlled, Double Blind Phase 3 Study Evaluating the Safety and Efficacy of the Addition of Velaparib Plus Carboplatin versus the Addition of Carobplatin to Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (Abbvie) Global Accrual = 634

Patient Population:
Patients with early-stage triple-negative breast cancer

Target Accrual: 16 patients

Status: Not Recruiting

ClinicialTrials.gov Identifier: NCT02032277